CIBC Private Wealth Group LLC reduced its holding in Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 3.0% in the third quarter, according to its latest Form 13F filed with the Securities and Exchange Commission. The company owned 1,916,447 shares of the medical research company after selling 58,671 shares during the quarter. CIBC Private Wealth Group LLC owned approximately 0.31% of Edwards Lifesciences, valued at $158,357,000 as of its latest filing with the Securities and Exchange Commission.
Many other institutional investors and hedge funds have also recently increased or decreased their stakes in the business. Covington Capital Management upped his Edwards Lifesciences stake by 2.6% in the third quarter. Covington Capital Management now owns 147,307 shares of the medical research company valued at $12,172,000 after acquiring an additional 3,745 shares during this period. CreativeOne Wealth LLC increased his position in Edwards Lifesciences by 2.4% in the third quarter. CreativeOne Wealth LLC now owns 11,972 shares of the medical research company worth $989,000 after purchasing an additional 282 shares during this period. Meiji Yasuda Life increased his position at Edwards LifeSciences by 6.6% in the third quarter. Meiji Yasuda Life Insurance Company now owns 11,934 shares of medical research company stock valued at $986,000 after purchasing an additional 738 shares during this period. United Services Automobile Association increased its position in Edwards Lifesciences by 6.5% in the third quarter. The United Services Automobile Association owns 24,346 shares of the medical research company valued at $2,011,000 after purchasing an additional 1,487 shares during this period. Finally, Verus Capital Partners LLC increased its position in Edwards Lifesciences by 220.0% in the third quarter. Verus Capital Partners LLC now owns 4,330 shares of the medical research company worth $358,000 after purchasing an additional 2,977 shares during this period. Hedge funds and other institutional investors own 80.35% of the company’s shares.
Wall Street Analyst Predicts Growth
Several equity analysts have commented on the company. Canaccord Genuity Group has raised Edwards Lifesciences’ price target from $68.00 to $76.00, giving the company a “pending” rating in its research report on Wednesday, February 1. Morgan Stanley raised Edwards’ price target for her life sciences from $92.00 to her $95.00 in a research report on Friday, Jan. 6, giving the company an “overweight” rating. Canaccord Genuity Group has lowered its price target for Edwards Lifesciences from $78.00 to $73.00 and placed the company’s rating on hold in its research report on Monday, December 12. Sanford C. Bernstein downgraded Edwards Lifesciences’ rating from ‘outperform’ to ‘underperform’ and lowered its stock price target from his $95.00 to his $66.00 in a research report on Tuesday, January 31. rice field. Finally, Citigroup lowered its price target for Edwards Lifesciences from $99.00 to $92.00, giving the company a ‘Buy’ rating in its research report on Monday, December 12th. 1 research analyst gave a sell rating, 10 gave a hold rating, and 8 gave a buy rating. Based on MarketBeat data, Edwards Lifesciences has an average rating of “pending” and an average price target of $88.95.
Edwards Lifesciences stock performance
EW shares climbed $0.75 during Monday’s trading hours to reach $75.09. His 1,670,977 shares in the company traded, with an average trading volume of 3,425,965 shares for him. Edwards Lifesciences Co. has a 12-month low of $67.13 and a 12-month high of $131.10. The company has a debt to equity ratio of 0.10, a current ratio of 3.03 and a quick ratio of 2.17. The company has a market capitalization of $45.68 billion, a P/E ratio of 30.47, a P/E/G ratio of 4.33 and a beta of 1.01. The company has a 50-day moving average price of $77.96 and a 200-day moving average price of $79.75.
Edwards Lifesciences (NYSE:EW – Get Rating) last reported quarterly results on Tuesday, January 31. The medical research firm reported an EPS of $0.64 for the quarter, beating analyst consensus expectations of $0.61 by $0.03. Edwards Lifesciences’ return on equity was 26.05% and net profit margin was 28.27%. The company posted revenue of $1.35 billion for the quarter, compared with analysts’ forecast of $1.33 billion. His EPS earnings for the company in the same period last year were $0.51. The company’s revenue increased by 1.5% compared to the same quarter last year. As a group, sell-side analysts expect Edwards Lifesciences Co. to post earnings per share of 2.52 for the current financial year.
In other news, Vice President Jean-Luc M. Lemercier sold 6,640 shares in the company in a transaction that occurred Wednesday, March 8th. The shares sold for an average of $76.96, and the total trading value he had was $511,014.40. Following the sale, the Vice President now directly owns 168,875 shares of the Company’s stock valued at approximately $12,996,620. The sale was disclosed in legal filings with the U.S. Securities and Exchange Commission, which can be accessed via this hyperlink. In other news, his vice president, Jean-Luc M. Lemercier, sold 6,640 shares of the company in a transaction that occurred Wednesday, March 8. The shares sold for an average of $76.96, and the total trading value he had was $511,014.40. Following the sale, the Vice President now directly owns 168,875 shares of the Company’s stock valued at approximately $12,996,620. The sale was disclosed in legal filings with the U.S. Securities and Exchange Commission, which can be accessed via this hyperlink. VP Donald E. Bobo, Jr. also sold 6,725 shares of the company in a transaction that took place on Monday, February 6th. The shares were sold at an average price of $80.75 for a total of $543,043.75. After the sale, the vice president now owns 62,561 shares in the company directly, valued at $5,051,800.75. Please see here for the disclosure of this sale. In the past three months, the insider has sold 101,386 shares of his company stock worth $7,834,077. A corporate insider owns his 1.29% of the company’s shares.
Edwards Life Science Company Profile
Edwards Lifesciences Corp. is committed to patient-centered medical innovation for cardiac and critical care monitoring. Its products fall into his four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Valve Treatment, Surgical Structural Cardiac, and Critical Care.
This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to email@example.com.
Before you consider Edwards Life Sciences, listen to this.
MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat has identified five stocks top analysts are quietly whispering to their clients to buy now before the broader market catches on…and Edwards Lifesciences is not on the list. bottom.
Edwards Lifesciences currently has a ‘Hold’ rating among analysts, but the top rated analysts believe these five stocks are better buys.
See 5 stocks here